Perrigo PE Ratio 2010-2025 | PRGO
Current and historical p/e ratio for Perrigo (PRGO) from 2010 to 2025. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Perrigo PE ratio as of June 06, 2025 is 9.11.
Please refer to the Stock Price Adjustment Guide for more information on our historical prices.
| Perrigo PE Ratio Historical Data | |||
|---|---|---|---|
| Date | Stock Price | TTM Net EPS | PE Ratio |
| 2025-06-06 | 26.16 | 0.00 | |
| 2025-03-31 | 27.74 | $-1.31 | 0.00 |
| 2024-12-31 | 25.18 | $-1.25 | 0.00 |
| 2024-09-30 | 25.44 | $-1.17 | 0.00 |
| 2024-06-30 | 24.67 | $-0.92 | 0.00 |
| 2024-03-31 | 30.62 | $-0.07 | 0.00 |
| 2023-12-31 | 30.31 | $-0.10 | 0.00 |
| 2023-09-30 | 29.82 | $0.05 | 596.36 |
| 2023-06-30 | 31.44 | $-0.42 | 0.00 |
| 2023-03-31 | 32.94 | $-0.96 | 0.00 |
| 2022-12-31 | 31.07 | $-0.96 | 0.00 |
| 2022-09-30 | 32.24 | $-0.63 | 0.00 |
| 2022-06-30 | 36.43 | $-0.70 | 0.00 |
| 2022-03-31 | 34.28 | $-0.65 | 0.00 |
| 2021-12-31 | 34.44 | $-0.35 | 0.00 |
| 2021-09-30 | 41.63 | $-1.88 | 0.00 |
| 2021-06-30 | 40.09 | $-2.57 | 0.00 |
| 2021-03-31 | 35.20 | $-1.70 | 0.00 |
| 2020-12-31 | 38.68 | $-1.21 | 0.00 |
| 2020-09-30 | 39.52 | $-0.06 | 0.00 |
| 2020-06-30 | 47.37 | $1.74 | 27.23 |
| 2020-03-31 | 41.05 | $1.37 | 29.96 |
| 2019-12-31 | 43.94 | $1.07 | 41.06 |
| 2019-09-30 | 47.34 | $1.81 | 26.15 |
| 2019-06-30 | 40.15 | $0.65 | 61.77 |
| 2019-03-31 | 40.42 | $0.84 | 48.12 |
| 2018-12-31 | 32.39 | $0.94 | 34.46 |
| 2018-09-30 | 59.00 | $0.86 | 68.61 |
| 2018-06-30 | 60.60 | $1.66 | 36.51 |
| 2018-03-31 | 69.10 | $0.91 | 75.94 |
| 2017-12-31 | 72.10 | $0.84 | 85.83 |
| 2017-09-30 | 69.90 | $-9.16 | 0.00 |
| 2017-06-30 | 62.23 | $-18.23 | 0.00 |
| 2017-03-31 | 54.59 | $-16.39 | 0.00 |
| 2016-12-31 | 68.29 | $-19.23 | 0.00 |
| 2016-09-30 | 75.63 | $-10.49 | 0.00 |
| 2016-06-30 | 74.15 | $-0.96 | 0.00 |
| 2016-03-31 | 104.47 | $-1.93 | 0.00 |
| 2015-12-31 | 118.03 | $-0.26 | 0.00 |
| 2015-09-30 | 128.17 | $0.99 | 129.46 |
| 2015-06-30 | 150.52 | $0.94 | 160.13 |
| 2015-03-31 | 134.74 | $0.56 | 240.60 |
| 2014-12-31 | 135.94 | $1.59 | 85.49 |
| 2014-09-30 | 122.05 | $0.21 | 581.21 |
| 2014-06-30 | 118.37 | $0.67 | 176.67 |
| 2014-03-31 | 125.50 | $0.67 | 187.31 |
| 2013-12-31 | 124.45 | $1.49 | 83.52 |
| 2013-09-30 | 99.99 | $3.48 | 28.73 |
| 2013-06-30 | 97.98 | $3.42 | 28.65 |
| 2013-03-31 | 96.08 | $3.42 | 28.09 |
| 2012-12-31 | 84.11 | $3.47 | 24.24 |
| 2012-09-30 | 93.84 | $3.41 | 27.52 |
| 2012-06-30 | 95.20 | $3.04 | 31.31 |
| 2012-03-31 | 83.33 | $3.04 | 27.41 |
| 2011-12-31 | 78.42 | $2.76 | 28.41 |
| 2011-09-30 | 78.20 | $2.67 | 29.29 |
| 2011-06-30 | 70.70 | $2.72 | 25.99 |
| 2011-03-31 | 63.93 | $2.72 | 23.50 |
| 2010-12-31 | 50.87 | $2.43 | 20.93 |
| 2010-09-30 | 51.52 | $2.01 | 25.63 |
| 2010-06-30 | 47.34 | $1.87 | 25.32 |
| 2010-03-31 | 47.01 | $1.87 | 25.14 |
| 2009-12-31 | 31.84 | $1.70 | 18.73 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Products Manufacturing | $3.596B | $4.373B |
| Perrigo Co. plc, with a diversified revenue stream, sells infant formulas for the store brand market, generic extended topical prescription (Rx) products and specialty pharmaceutical drugs. It's focusing on self-care products as part of its transformation into a self-care company from a healthcare company. The company divested its Rx segment to Altaris Capital Partners. The company completed its transformation to a consumer self-care company by reconfiguring the portfolio through the divestiture of RX business. Currently, the company has 2 reporting segments. Consumer Self Care Americas (CSCA): The segment comprises the U.S., Mexico and Canada CHC business, including OTC, contract manufacturing, infant formula and animal health categories. Consumer Self Care International?(CSCI): The segment comprises the branded consumer healthcare (BCH) segment mainly in Europe and the company's consumer-focused businesses in the UK and Australia. This segment includes UK liquids licensed products business. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Abbott Laboratories (ABT) | United States | $232.407B | 27.95 |
| Boston Scientific (BSX) | United States | $151.037B | 37.81 |
| Stryker (SYK) | United States | $146.527B | 30.64 |
| EssilorLuxottica (ESLOY) | France | $129.703B | 0.00 |
| Medtronic (MDT) | Ireland | $112.146B | 15.90 |
| Lonza Group Ag (LZAGY) | Switzerland | $50.313B | 0.00 |
| Haleon (HLN) | United Kingdom | $49.826B | 28.39 |
| ResMed (RMD) | United States | $36.979B | 27.77 |
| Agilent Technologies (A) | United States | $32.895B | 21.44 |
| GE HealthCare Technologies (GEHC) | United States | $32.794B | 15.57 |
| Terumo (TRUMY) | Japan | $26.561B | 34.50 |
| Koninklijke Philips (PHG) | Netherlands | $22.051B | 15.85 |
| Insulet (PODD) | United States | $21.941B | 86.12 |
| Zimmer Biomet Holdings (ZBH) | United States | $18.277B | 11.74 |
| Baxter (BAX) | United States | $15.529B | 11.59 |
| Smith & Nephew SNATS (SNN) | United Kingdom | $13.253B | 0.00 |
| Demant (WILYY) | Denmark | $8.854B | 0.00 |
| Sunny Optical Technology (SNPTF) | China | $8.430B | 0.00 |
| Bio-Rad Laboratories (BIO) | United States | $5.971B | 20.78 |
| Lantheus Holdings (LNTH) | United States | $5.642B | 14.23 |
| Prestige Consumer Healthcare (PBH) | United States | $4.203B | 18.78 |
| Shandong Weigao Medical Polymer (SHWGF) | China | $3.459B | 0.00 |
| Haemonetics (HAE) | United States | $3.385B | 15.42 |
| ICU Medical (ICUI) | United States | $3.275B | 24.15 |
| Envista Holdings (NVST) | United States | $3.174B | 26.38 |
| GN Store Nord (GNNDY) | Denmark | $2.180B | 18.06 |
| QuidelOrtho (QDEL) | United States | $1.997B | 13.73 |
| LeMaitre Vascular (LMAT) | United States | $1.901B | 42.49 |
| AtriCure (ATRC) | United States | $1.730B | 0.00 |
| Acuren (TIC) | United States | $1.271B | 0.00 |
| AdaptHealth (AHCO) | United States | $1.201B | 12.19 |
| Neogen (NEOG) | United States | $1.131B | 14.47 |
| BioLife Solutions (BLFS) | United States | $1.126B | 0.00 |
| Green Thumb Industries (GTBIF) | United States | $1.100B | 24.74 |
| Kestra Medical Technologies (KMTS) | United States | $1.063B | 0.00 |
| Phibro Animal Health (PAHC) | United States | $0.976B | 12.48 |
| InMode (INMD) | Israel | $0.895B | 9.02 |
| Capricor Therapeutics (CAPR) | United States | $0.650B | 0.00 |
| Evolus (EOLS) | United States | $0.647B | 0.00 |
| CeriBell (CBLL) | United States | $0.647B | 0.00 |
| Owens & Minor (OMI) | United States | $0.619B | 5.13 |
| Maravai LifeSciences Holdings (MRVI) | United States | $0.609B | 0.00 |
| Curaleaf Holdings (CURLF) | Canada | $0.584B | 0.00 |
| Valneva SE (VALN) | France | $0.524B | 0.00 |
| Surmodics (SRDX) | United States | $0.420B | 0.00 |
| Tilray Brands (TLRY) | Canada | $0.408B | 0.00 |
| VAREX IMAGING (VREX) | United States | $0.347B | 12.76 |
| SNDL (SNDL) | Canada | $0.347B | 0.00 |
| Aurora Cannabis (ACB) | Canada | $0.322B | 57.20 |
| Canopy Growth (CGC) | Canada | $0.313B | 0.00 |
| SEMPERIT AG HLD (SEIGY) | Austria | $0.291B | 0.00 |
| Cerus (CERS) | United States | $0.289B | 0.00 |
| Viemed Healthcare (VMD) | United States | $0.266B | 22.40 |
| Cresco Labs (CRLBF) | United States | $0.265B | 0.00 |
| Sanara MedTech (SMTI) | United States | $0.262B | 0.00 |
| ZimVie (ZIMV) | United States | $0.261B | 11.87 |
| Sanuwave Health (SNWV) | United States | $0.239B | 0.00 |
| Omeros (OMER) | United States | $0.221B | 0.00 |
| OraSure Technologies (OSUR) | United States | $0.216B | 0.00 |
| Biote (BTMD) | United States | $0.210B | 5.89 |
| Quanterix (QTRX) | United States | $0.209B | 0.00 |
| TriSalus Life Sciences (TLSI) | United States | $0.204B | 0.00 |
| Brainsway (BWAY) | Israel | $0.197B | 52.25 |
| High Tide (HITI) | Canada | $0.193B | 0.00 |
| Verano Holdings (VRNOF) | United States | $0.192B | 0.00 |
| Utah Medical Products (UTMD) | United States | $0.182B | 14.86 |
| Organigram Global (OGI) | Canada | $0.181B | 0.00 |
| Exagen (XGN) | United States | $0.154B | 0.00 |
| Vireo Growth (VREOF) | United States | $0.139B | 0.00 |
| FitLife Brands (FTLF) | United States | $0.134B | 0.00 |
| Jin Medical (ZJYL) | China | $0.120B | 0.00 |
| MacroGenics (MGNX) | United States | $0.112B | 0.00 |
| Oramed Pharmaceuticals (ORMP) | United States | $0.091B | 0.00 |
| Veru (VERU) | United States | $0.091B | 0.00 |
| Fonar (FONR) | United States | $0.090B | 11.59 |
| Quipt Home Medical (QIPT) | United States | $0.087B | 0.00 |
| TerrAscend (TSNDF) | Canada | $0.082B | 0.00 |
| Agape ATP (ATPC) | $0.077B | 0.00 | |
| InterCure (INCR) | Israel | $0.068B | 0.00 |
| Cytosorbents (CTSO) | United States | $0.066B | 0.00 |
| Zynex (ZYXI) | United States | $0.066B | 0.00 |
| Apyx Medical (APYX) | United States | $0.063B | 0.00 |
| ImmuCell (ICCC) | United States | $0.059B | 0.00 |
| Jushi Holdings (JUSHF) | United States | $0.058B | 0.00 |
| Modular Medical (MODD) | United States | $0.046B | 0.00 |
| United-Guardian (UG) | United States | $0.038B | 13.14 |
| Nephros (NEPH) | United States | $0.036B | 48.00 |
| Rockwell Medical (RMTI) | United States | $0.035B | 0.00 |
| Safety Shot (SHOT) | United States | $0.020B | 0.00 |
| Allurion Technologies (ALUR) | United States | $0.020B | 0.00 |
| Meihua Medical Technologies (MHUA) | China | $0.019B | 0.00 |
| Cellectar Biosciences (CLRB) | United States | $0.017B | 0.00 |
| INLIF (INLF) | $0.016B | 0.00 | |
| Flora Growth (FLGC) | United States | $0.014B | 0.00 |
| Trinity Biotech (TRIB) | Ireland | $0.012B | 0.00 |
| Innovative Eyewear (LUCY) | United States | $0.009B | 0.00 |
| IM Cannabis (IMCC) | Canada | $0.006B | 0.00 |
| Senestech (SNES) | United States | $0.005B | 0.00 |
| GlucoTrack (GCTK) | United States | $0.004B | 0.00 |
| Akanda (AKAN) | Canada | $0.002B | 0.00 |
| Sharps Technology (STSS) | United States | $0.000B | 0.00 |
| InVivo Therapeutics Holdings (NVIVQ) | United States | $0.000B | 0.00 |